A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
High efficacy of therapeutic equine hyperimmune antibodies against SARS CoV-2 variants of concern
[article]
2021
bioRxiv
pre-print
Preserved Fulltext
SARS-CoV-2 variants of concern (VoC) show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies. We tested therapeutic equine polyclonal antibodies (pAbs) against four VoC (alpha, beta, epsilon and gamma). We show that equine pAbs efficiently neutralize VoC, suggesting they are an effective, broad coverage, low-cost and a scalable COVID-19 treatment.
doi:10.1101/2021.06.12.448080
fatcat:yhbbbnbxrnhmjoynruewx7ut5y